THE BRIGHAM AND WOMEN'S HOSPITAL, INC.;DANA-FARBER CANCER INSTITUTE;EMORY UNIVERSITY;PRESIDENT AND FELLOWS OF HARVARD COLLEGE
发明人:
FREEMAN, GORDON,SHARPE, ARLENE,DORFMAN, DAVID, M,AHMED, RAFI,BARBER, DANIEL,WHERRY, JOHN, E
申请号：
NZ59030806
公开号：
NZ590308A
申请日:
2006.06.08
申请国别(地区):
NZ
年份:
2012
代理人:
摘要：
Disclosed is the use of a Programmed Cell Death-1 (PD-1) inhibitor in the manufacture of a medicament formulated to treat a tumor in a subject, wherein said PD-1 inhibitor is an anti-PD-1 antibody, an anti-PD-L1 antibody, an anti-PD-L2 antibody, an anti-PD-1 RNAi, an anti-PD-Ll RNAi, an anti-PD-L2 RNAi, an anti-PD-I antisense RNA, an anti-PD-L1 antisense RNA, an anti-PD-L2 antisense RNA, a dominant negative PD-1 protein, a dominant negative PD-L1 protein, or a dominant negative PD-L2 protein, wherein said tumor is angioimmunoblastic lymphoma, or nodular lymphocyte predominant Hodgkin's lymphoma.
